Atara Biotherapeutics (ATRA) Gains from Investment Securities (2014 - 2025)
Atara Biotherapeutics (ATRA) reported Gains from Investment Securities of -$60000.0 for Q4 2025, down 106.91% on a YoY basis from $868000.0 in Q4 2024, and down 115.54% quarter-over-quarter from $386068.0 in Q3 2025.
Atara Biotherapeutics (ATRA) Gains from Investment Securities (2014 - 2025) Analysis & Trends
Atara Biotherapeutics has reported Gains from Investment Securities for 12 years, with the latest figure at -$60000.0 in Q4 2025.
- For the quarter ending Q4 2025, Gains from Investment Securities fell 106.91% year-over-year to -$60000.0; the trailing twelve-month figure through Mar 2026 stood at $1.0 million (changed N/A YoY), and the FY2025 full-year result was $72290.0, up 338.12% from the prior year.
- Gains from Investment Securities for Q4 2025 stood at -$60000.0, down from $386068.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $50.2 million in Q4 2022, with the low at -$177000.0 in Q4 2021.
- Historically, Gains from Investment Securities has averaged $4.1 million across 5 years, with a median of $450853.5 in 2021.
- Annual changes were most pronounced in 2022 — Gains from Investment Securities jumped 28471.75% — and 2025, when it slumped 106.91%.
- Atara Biotherapeutics' Gains from Investment Securities stood at -$177000.0 in 2021, then jumped by 28471.75% to $50.2 million in 2022, then tumbled by 96.28% to $1.9 million in 2023, then tumbled by 53.57% to $868000.0 in 2024, then plunged by 106.91% to -$60000.0 in 2025.
- The last three Gains from Investment Securities figures came in at -$60000.0 (Q4 2025), $386068.0 (Q3 2025), and $386068.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - |
| 10 | Atara Biotherapeutics | 137.85 Mn | 129.45 Mn | 392,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -60,000.00 |
| Dec 31, 2025 | -60,000.00 |
| Sep 30, 2025 | 386,068.00 |
| Sep 30, 2025 | 386,068.00 |
| Jun 30, 2025 | 386,068.00 |
| Jun 30, 2025 | 386,068.00 |
| Dec 31, 2024 | 868,000.00 |
| Dec 31, 2024 | 868,000.00 |
| Sep 30, 2024 | 119,857.00 |
| Sep 30, 2024 | 119,857.00 |
| Jun 30, 2024 | 121,311.00 |
| Jun 30, 2024 | 121,311.00 |
| Mar 31, 2024 | 227,000.00 |
| Mar 31, 2024 | 227,000.00 |
| Sep 30, 2023 | 1.87 Mn |
| Sep 30, 2023 | 1.87 Mn |
| Jun 30, 2023 | 1.93 Mn |
| Jun 30, 2023 | 1.93 Mn |
| Mar 31, 2023 | 312,000.00 |
| Mar 31, 2023 | 312,000.00 |